Predict your next investment

Pre Diagnostics company logo
HEALTHCARE | Disease Diagnosis

See what CB Insights has to offer


Grant | Alive

Total Raised


About Pre Diagnostics

Pre Diagnostics is a Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases. The company's proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients.

Pre Diagnostics Headquarter Location


Oslo, 0115,


Latest Pre Diagnostics News

PreADx Alzheimer’s Detection Immunoassay Proof of Concept Study Successful

Apr 1, 2021

Pre Diagnostics, an Oslo, Norway-based healthtech company developing novel blood tests for neurodegenerative diseases, announced that its PreADx immunoassay for early detection of Alzheimer’s Disease has successfully completed a clinical evaluation. The company now plans to further optimize the assay in advance of CE marking in Q2, 2021. Unlike plasma or serum-based assays, PreADx takes an intracellular approach and measures the clearance of beta-amyloid peptides by analyzing a patient’s monocytes. The monocytes are a part of the innate immune system, and stem from the same cell lineage as the microglia and macrophages that clear plaques in the brain. In the blind evaluation of 62 well-characterized samples and controls from the Norwegian multicenter study “Dementia Disease Initiative,” PreADx achieved an ROC AUC of .81 in distinguishing healthy controls from Alzheimer’s patients. This is in line with the generally recognized threshold for diagnostic accuracy and opens the way for development of a much-needed new wave of early Alzheimer’s Disease assays. “In both my clinical work and the Dementia Disease Initiative, I have seen the pressing need for more early diagnostic tools. I am pleased to see that the concept of extracting relevant information about neurodegenerative diseases from monocytes first discovered back in 2009, now has been validated in this study. I believe integrating AD diagnostics with innate immunity may also be helpful for precision medicine strategies,” says Professor Tormod Fladby, MD PhD, main inventor and head of the Department of Neurology at Akershus University Hospital. “Beta-amyloid aggregation is generally considered the first pathological sign of the disease which is why we believe that a validated non-invasive immunoassay that can detect this will prove an invaluable front-line tool for improving Alzheimer’s Disease detection and treatment,” says Charlotte Berg-Svendsen, CCO, Pre Diagnostics AS. “In preparation for CE marking we will now run further samples using an optimized version of the assay, which should also lead to increased accuracy. Further analysis will also give us a better picture of the potential clinical utility of this new biomarker, both alone and in combination with gender, ApoE and age.” This development project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 849834. Share:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pre Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pre Diagnostics is included in 1 Expert Collection, including Medical Devices.


Medical Devices

7,423 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

Pre Diagnostics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pre Diagnostics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.